Pds biotech enrolls first stage of checkpoint inhibitor naÏve patient arm of phase 2 clinical trial in advanced hpv-16 positive head and neck cancer

Florham park, n.j., oct. 04, 2021 (globe newswire) -- pds biotechnology corporation (nasdaq: pdsb), a clinical-stage immunotherapy company developing novel cancer therapies based on the company's proprietary versamune® t-cell activating technology, today announced the completion of enrollment for the first stage of the checkpoint inhibitor naÏve arm of its versatile-002 phase 2 study for the treatment of recurrent and/or metastatic human papillomavirus (hpv16)-associated head and neck cancer. 90% of hpv-associated head and neck cancers are reported to be caused by hpv16 as reported by a study published in the journal of clinical medicine.
PDSB Ratings Summary
PDSB Quant Ranking